SLC40A1 and cancer: Given that cancer cells often manifest an increased intracellular iron concentration due to a high level of expression of transferrin receptor 1 (which mediates cellular iron uptake) and a low abundance of ferroportin (which contributes to iron efflux) [15], xCT-targeted therapy is expected to effectively induce ferroptosis in cancer cells without affecting normal tissue.